Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Barth, DA; Stanzer, S; Spiegelberg, J; Bauernhofer, T; Absenger, G; Posch, F; Lipp, R; Halm, M; Szkandera, J; Balic, M; Gerger, A; Smolle, MA; Hutterer, GC; Klec, C; Jost, PJ; Kargl, J; Stradner, M; Pichler, M.
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Cancer Med. 2022; 11(16):3074-3083
Doi: 10.1002/cam4.4675
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Barth Dominik Andreas
- Pichler Martin
- Co-Autor*innen der Med Uni Graz
- Absenger Gudrun
- Balic Marija
- Bauernhofer Thomas
- Gerger Armin
- Halm Michael
- Hutterer Georg
- Jost Philipp
- Kargl Julia
- Klec Christiane
- Lipp Rainer
- Posch Florian
- Smolle Maria Anna
- Spiegelberg Jasmin Alija
- Stanzer Stefanie
- Stradner Martin Helmut
- Szkandera Joanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The presence of autoantibodies in the serum of cancer patients has been associated with immune-checkpoint inhibitor (ICI) therapy response and immune-related adverse events (irAEs). A prospective evaluation of different autoantibodies in different cancer entities is missing. MATERIALS AND METHODS: In this prospective cohort study, we included a pan-cancer cohort of patients undergoing ICI treatment and measured a comprehensive panel of autoantibodies at treatment start and at the time point of first response evaluation. The presence and induction of autoantibodies (ANA, ENA, myositis, hepatopathy, rheumatoid arthritis) in different cancer entities were assessed and the association between autoantibodies and disease control rate (DCR), objective response rate (ORR), and progression-free survival (PFS), as well as the development of grade 3 or higher irAEs were evaluated by logistic regression models, cox proportional hazard models, and Kaplan-Meier estimators. RESULTS: Of 44 patients with various cancer entities, neither the presence of any positive autoantibody measurement nor the presence of positive antinuclear antibodies (ANA) [≥1:80] at baseline was associated with the examined clinical endpoints (DCR, ORR, PFS) in univariable and multivariable analyses. After 8-12 weeks of ICI treatment, DCR, ORR, and PFS did not significantly differ between patients with and without any positive autoantibody measurement or positive ANA titers. The frequency of irAEs did not differ depending on autoantibody status of the patients. CONCLUSION: Autoantibodies at treatment initiation or induction after 8-12 weeks of ICI treatment are not associated with treatment efficacy as indicated by DCR, ORR, and PFS or higher grade irAEs.
- Find related publications in this database (using NLM MeSH Indexing)
- Autoantibodies - administration & dosage
- Drug-Related Side Effects and Adverse Reactions - administration & dosage
- Humans - administration & dosage
- Immune Checkpoint Inhibitors - adverse effects
- Neoplasms - drug therapy
- Prospective Studies - administration & dosage
- Find related publications in this database (Keywords)
- autoimmunity
- cancer
- immune checkpoint inhibitor therapy
- immune-related adverse events
- monoclonal antibodies